Investigators of the SWOG S1007 RxPONDER trial found a statistically significant improvement in invasive disease-free survival and distant relapse-free survival in premenopausal women who received adjuvant chemotherapy.
Jonah Feldman
Advertisement
Articles by Jonah Feldman
Advertisement
Latest Updated Articles
Survival benefit for chemotherapy addition demonstrated for premenopausal patients with HR+/HER2– breast cancerPublished: December 24th 2021 | Updated:
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Mikael Björnson, MD, links long COVID and POTS
2
US stillbirth rates greater than previously reported
3
Cardiovascular disease prevention in women: A discussion with Erin Donnelly Michos, MD
4
Special Report: Managing vasomotor symptoms in menopause
5
